Motif Bio’s hope of adding to the antibiotic armamentarium for serious bacterial infections has just been dealt a blow by the FDA.

Amgen and Abilita Bio have inked a research deal, focusing on developing drugs for challenging membrane protein targets.

A team led by the Wyss Institute has created reversible platelets that they say may not only reduce blood clots but might also prevent cancer from spreading.

Johnson & Johnson is diving deeper into robotic surgery with a $3.4 billion deal for Auris Health, designer of endoscopes aimed at lung cancer.

Charles River has added another string to its early-stage R&D bow by acquiring preclinical services firm Citoxlab for $510 million in cash.

The deal sees Sygnature take a stake in Pathios in part payment for its involvement in the Oxford-based biotech’s hit-to-lead program.

The panel’s decision to back the ketamine-like drug tees J&J up to win approval for one of the most notable antidepressants in decades.

5AM Ventures has closed two new biotech-focused capital funds, totaling $497 million in commitments.